Sentinel lymph node biopsy in patients with ductal carcinoma in situ
- 28 June 2002
- Vol. 95 (1) , 15-20
- https://doi.org/10.1002/cncr.10641
Abstract
Sentinel lymph node (SLN) biopsy for the treatment of ductal carcinoma in situ (DCIS) is not necessary and generally should be limited to those patients with a core needle biopsy diagnosis of DCIS who are undergoing mastectomy. Used in this way, SLN biopsy will spare the majority of patients with occult invasive tumor the need for axillary lymph node dissection.Keywords
This publication has 31 references indexed in Scilit:
- Occult Metastases in Sentinel Nodes of 200 Patients With Operable Breast CancerAnnals of Surgical Oncology, 2001
- Is It Really Duct Carcinoma In Situ?Annals of Surgical Oncology, 2001
- Sentinel Node Biopsy for Patients With DCIS: A Dangerous and Unwarranted DirectionAnnals of Surgical Oncology, 2001
- Sentinel Lymph Node Biopsy: Is It Indicated in Patients With High-Risk Ductal Carcinoma-In-Situ and Ductal Carcinoma-In-Situ With Microinvasion?Annals of Surgical Oncology, 2000
- Axillary Metastases With DCIS: Is the Glass Half Empty or Half Full?Annals of Surgical Oncology, 2000
- Benign Transport of Breast Epithelium Into Axillary Lymph Nodes After BiopsyAmerican Journal of Clinical Pathology, 2000
- Sentinel-Lymph-Node Biopsy for Breast Cancer — Not Yet the Standard of CareNew England Journal of Medicine, 1998
- The Sentinel Node in Breast Cancer — A Multicenter Validation StudyNew England Journal of Medicine, 1998
- The breast imaging reporting and data system: positive predictive value of mammographic features and final assessment categories.American Journal of Roentgenology, 1998
- Lymphatic Mapping and Sentinel Lymphadenectomy for Breast CancerAnnals of Surgery, 1994